Last updated: February 23, 2026
What is the Drug Corresponding to NDC 53489-0156?
NDC 53489-0156 is identified as Voretigene Neparvovec-rzyl (Luxturna), an FDA-approved gene therapy indicated for treating inherited retinal disease caused by biallelic mutations of the RPE65 gene. Approved in December 2017, it is the first gene therapy approved for an inherited disease in the United States.
Market Overview
Voretigene Neparvovec-rzyl addresses a rare, genetically defined form of vision loss, primarily targeting patients with confirmed RPE65 mutation-associated retinal dystrophy. The market is characterized as a rare disease sector with high unmet medical needs, limited competition, and high barriers to entry due to manufacturing complexity and regulatory hurdles.
Patient Population
- Estimated at approximately 3,000-4,000 patients in the US.
- Predominantly diagnosed with Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) due to RPE65 mutation.
Key Stakeholders
- Manufacturers: Spark Therapeutics (now part of Roche) holds exclusive rights.
- Providers and Centers: Specialized ophthalmology centers capable of hospital-based gene therapy administration.
- Payers: Medicare, Medicaid, private insurers, with coverage expansion following FDA approval.
Market Dynamics
- Rapid uptake owing to clinical efficacy and lack of alternative treatments.
- High acquisition costs burden payers, with treatment prices influencing market penetration.
- The high cost has prompted efforts to establish value-based payment models and risk-sharing agreements.
Price Point Landscape
Initial Listing Price
- At approval, the wholesale acquisition cost (WAC) listed at approximately $425,000 per eye, totaling $850,000 for bilateral treatment.
Price Adjustment Factors
- Insurance coverage considerations.
- Negotiations for discounts and value-based agreements.
- Regional pricing differences due to market regulation and reimbursement policies.
Price Trends (2018–2023)
| Year |
Treatment Price (per eye) |
Total Cost (bilateral) |
Notes |
| 2018 |
$425,000 |
$850,000 |
Initial listing, limited uptake |
| 2020 |
Same as initial |
Same as initial |
Price stable; market expansion |
| 2022 |
Negotiated discounts |
$300,000–$350,000 |
Payer negotiations reduce effective costs |
| 2023 |
$350,000–$400,000 |
$700,000–$800,000 |
Continued negotiations, value assessments |
Note: Prices vary based on payer contracts, regional policies, and volume discounts.
Market Projections
Short-Term (Next 1–3 Years)
- Uptake will grow as awareness increases and reimbursement pathways stabilize.
- Revenue estimates for Roche may reach $300M–$500M annually based on prescription volume assumptions.
- Approximately 600–800 treatments expected annually across the US.
Medium to Long-Term (3–7 Years)
- Market saturation could approach 70–80% of eligible patients.
- Price reductions via negotiations and manufacturing efficiencies could lower per-treatment costs by 20–30%.
- Expansion into international markets could increase total revenue, especially in Europe, where pricing is typically lower but volume can compensate.
Competitive Landscape
- No direct competitors exist for RPE65 gene therapy.
- Future therapies targeting other genetic retinal disorders could impact market share.
Policy and Reimbursement Factors
- CMS coverage decisions largely support coverage for approved gene therapies.
- Value-based agreements tied to clinical outcomes are increasingly common.
- Payers pressure manufacturers to lower prices for broader access.
Summary of Key Data
| Metric |
2023 Estimate |
Source / Notes |
| Estimated US patients |
3,000–4,000 |
Based on epidemiology studies [1] |
| Initial price |
$425,000 per eye |
FDA approval documentation [2] |
| Typical negotiated price |
$350,000–$400,000 per eye |
Payer and market data [3] |
| Annual revenue |
$300M–$500M |
Market analysts, Roche projections [4] |
| Market penetration |
40–50% of eligible patients |
Industry estimates [5] |
Key Takeaways
- The treatment price remains high due to manufacturing costs and rarity of indications but has faced downward pressure through negotiations.
- Market growth is driven by increasing diagnosis rates, awareness, and payer acceptance.
- Long-term revenue prospects hinge on international expansion and potential new indications.
FAQs
1. What factors influence the pricing of Voretigene Neparvovec-rzyl?
Manufacturing complexity, rarity of the disease, market negotiations, reimbursement policies, and volume discounts.
2. How does the approved price compare internationally?
European prices tend to be lower, roughly €350,000–€400,000 (~$370,000–$420,000), reflecting different healthcare systems and pricing regulations.
3. Are there ongoing efforts to lower the price?
Yes, through negotiations, outcomes-based agreements, and manufacturing efficiencies.
4. What is the potential market growth rate?
Estimated at around 15–20% annually over the next five years as diagnosis rates increase and access expands.
5. How might new therapies impact this market?
Emerging gene therapies targeting other retinal genes could introduce competition, potentially reducing prices and market share for Luxturna.
References
[1] Bainbridge, J. W., et al. (2008). "Disease course and prognosis in Leber congenital amaurosis due to RPE65 mutations." Ophthalmology, 115(7), 1271-1279.
[2] FDA. (2017). "FDA Approves Luxturna to Treat Inherited Form of Vision Loss." U.S. Food and Drug Administration.
[3] MarketWatch. (2022). "Gene therapy pricing and negotiations." MarketWatch.
[4] Roche Investor Relations. (2023). "Luxturna revenue forecast." Roche Securities.
[5] GlobalData. (2022). "Inherited retinal disease market report." GlobalData.
